HCWB HCW Biologics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HCWB

Price (delayed)

$1.33

Market cap

$50.31M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.7

Enterprise value

$53.01M

Highlights
HCW Biologics's quick ratio has shrunk by 95% YoY and by 73% QoQ
HCW Biologics's gross profit has plunged by 78% YoY and by 2.7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of HCWB
Market
Shares outstanding
37.82M
Market cap
$50.31M
Enterprise value
$53.01M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.55
Price to sales (P/S)
85.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
94.61
Earnings
Revenue
$560,360
EBIT
-$24.71M
EBITDA
-$23.58M
Free cash flow
-$28.72M
Per share
EPS
-$0.7
Free cash flow per share
-$0.8
Book value per share
$0.37
Revenue per share
$0.02
TBVPS
$0.79
Balance sheet
Total assets
$28.51M
Total liabilities
$15.05M
Debt
$6.3M
Equity
$13.46M
Working capital
-$2.34M
Liquidity
Debt to equity
0.47
Current ratio
0.73
Quick ratio
0.59
Net debt/EBITDA
-0.11
Margins
EBITDA margin
-4,207.3%
Gross margin
100%
Net margin
-4,460.4%
Operating margin
-4,589.4%
Efficiency
Return on assets
-67.9%
Return on equity
-101.5%
Return on invested capital
-91%
Return on capital employed
-125%
Return on sales
-4,409.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HCWB stock price

How has the HCW Biologics stock price performed over time
Intraday
-1.48%
1 week
-4.32%
1 month
-19.88%
1 year
-3.62%
YTD
8.57%
QTD
-24.43%

Financial performance

How have HCW Biologics's revenue and profit performed over time
Revenue
$560,360
Gross profit
$560,360
Operating income
-$25.72M
Net income
-$24.99M
Gross margin
100%
Net margin
-4,460.4%
HCW Biologics's gross profit has plunged by 78% YoY and by 2.7% from the previous quarter
HCWB's revenue has dropped by 78% year-on-year and by 2.7% since the previous quarter
The operating income has dropped by 71% year-on-year and by 25% since the previous quarter
The net income has dropped by 68% year-on-year and by 27% since the previous quarter

Growth

What is HCW Biologics's growth rate over time

Valuation

What is HCW Biologics stock price valuation
P/E
N/A
P/B
3.55
P/S
85.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
94.61
HCWB's EPS has dropped by 67% year-on-year and by 25% since the previous quarter
HCW Biologics's equity has plunged by 64% YoY and by 44% from the previous quarter
The P/B is 37% higher than the last 4 quarters average of 2.6
HCWB's revenue has dropped by 78% year-on-year and by 2.7% since the previous quarter
HCWB's price to sales (P/S) is 6% less than its last 4 quarters average of 90.3

Efficiency

How efficient is HCW Biologics business performance
The ROE has dropped by 199% year-on-year and by 58% since the previous quarter
The ROA has shrunk by 124% YoY and by 42% QoQ
HCWB's return on invested capital has dropped by 84% year-on-year and by 34% since the previous quarter
HCWB's ROS is down by 31% since the previous quarter

Dividends

What is HCWB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HCWB.

Financial health

How did HCW Biologics financials performed over time
HCWB's total assets is 89% greater than its total liabilities
HCW Biologics's quick ratio has shrunk by 95% YoY and by 73% QoQ
The company's current ratio has shrunk by 94% YoY and by 71% QoQ
The company's debt is 53% lower than its equity
HCW Biologics's debt to equity has surged by 176% YoY and by 74% QoQ
HCW Biologics's equity has plunged by 64% YoY and by 44% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.